Cargando…
Analytical validation of a novel point‐of‐care immunoassay for canine N‐terminal pro‐brain natriuretic peptide analysis
BACKGROUND: N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) is a widely used point‐of‐care (POC) cardiac biomarker in human medicine. Canine NT‐proBNP is used less in veterinary medicine, possibly due to the lack of a POC canine NT‐proBNP assay resulting in temporal delay, increased degradation...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544283/ https://www.ncbi.nlm.nih.gov/pubmed/35312100 http://dx.doi.org/10.1111/vcp.13101 |
_version_ | 1784804563492012032 |
---|---|
author | Harr, Kendal E. Gordon, Sonya G. Baumwart, Ryan D. Feldgreber, Ross Spiro, Matthew R. |
author_facet | Harr, Kendal E. Gordon, Sonya G. Baumwart, Ryan D. Feldgreber, Ross Spiro, Matthew R. |
author_sort | Harr, Kendal E. |
collection | PubMed |
description | BACKGROUND: N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) is a widely used point‐of‐care (POC) cardiac biomarker in human medicine. Canine NT‐proBNP is used less in veterinary medicine, possibly due to the lack of a POC canine NT‐proBNP assay resulting in temporal delay, increased degradation in transport, and high reported variability in the available assay. A new quantitative POC analyzer allows fast, onsite measurement of NT‐proBNP, minimizing preanalytical error and reducing variability. OBJECTIVE: We aimed to analytically validate an NT‐proBNP assay (Vcheck) according to American Society of Veterinary Clinical Pathology (ASVCP) and Clinical Laboratory Improvement Amendments (CLIA) specifications. METHODS: Archived and prospective plasma and serum samples were collected from male and female, client‐owned dogs of various breeds with cardiac abnormalities (n = 81) and a healthy control population (n = 225). Precision, accuracy, analytical sensitivity, and specificity, and other statistical analyses were performed. RESULTS: Imprecision was considered acceptable with a coefficient of variation ranging from 9% at 4000 pmol/L to 20% at 600 pmol/L. The lower limit of quantitation was 650 pmol/L based on repetitive measures evaluation. Comparison of the Vcheck assay with the Cardiopet NT‐proBNP assay revealed an excellent correlation with minimal bias when preanalytical factors were controlled. Significant degradation of NT‐proBNP occurred when current methods were used at refrigerated and room temperatures, which could change diagnostic and prognostic decision‐making. Age‐partitioned reference intervals have high reference values of 750 pmol/L and 1280 pmol/L for juvenile and adult dogs, respectively. CONCLUSIONS: The Vcheck NT‐ProBNP assay provides analytically acceptable results. Onsite testing can minimize variability related to preanalytical error and provide clinically useful contemporaneous results. Samples should be centrifuged immediately and analyzed within 2 hours of collection. |
format | Online Article Text |
id | pubmed-9544283 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95442832022-10-14 Analytical validation of a novel point‐of‐care immunoassay for canine N‐terminal pro‐brain natriuretic peptide analysis Harr, Kendal E. Gordon, Sonya G. Baumwart, Ryan D. Feldgreber, Ross Spiro, Matthew R. Vet Clin Pathol Clinical Chemistry BACKGROUND: N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) is a widely used point‐of‐care (POC) cardiac biomarker in human medicine. Canine NT‐proBNP is used less in veterinary medicine, possibly due to the lack of a POC canine NT‐proBNP assay resulting in temporal delay, increased degradation in transport, and high reported variability in the available assay. A new quantitative POC analyzer allows fast, onsite measurement of NT‐proBNP, minimizing preanalytical error and reducing variability. OBJECTIVE: We aimed to analytically validate an NT‐proBNP assay (Vcheck) according to American Society of Veterinary Clinical Pathology (ASVCP) and Clinical Laboratory Improvement Amendments (CLIA) specifications. METHODS: Archived and prospective plasma and serum samples were collected from male and female, client‐owned dogs of various breeds with cardiac abnormalities (n = 81) and a healthy control population (n = 225). Precision, accuracy, analytical sensitivity, and specificity, and other statistical analyses were performed. RESULTS: Imprecision was considered acceptable with a coefficient of variation ranging from 9% at 4000 pmol/L to 20% at 600 pmol/L. The lower limit of quantitation was 650 pmol/L based on repetitive measures evaluation. Comparison of the Vcheck assay with the Cardiopet NT‐proBNP assay revealed an excellent correlation with minimal bias when preanalytical factors were controlled. Significant degradation of NT‐proBNP occurred when current methods were used at refrigerated and room temperatures, which could change diagnostic and prognostic decision‐making. Age‐partitioned reference intervals have high reference values of 750 pmol/L and 1280 pmol/L for juvenile and adult dogs, respectively. CONCLUSIONS: The Vcheck NT‐ProBNP assay provides analytically acceptable results. Onsite testing can minimize variability related to preanalytical error and provide clinically useful contemporaneous results. Samples should be centrifuged immediately and analyzed within 2 hours of collection. John Wiley and Sons Inc. 2022-03-20 2022-09 /pmc/articles/PMC9544283/ /pubmed/35312100 http://dx.doi.org/10.1111/vcp.13101 Text en © 2022 The Authors. Veterinary Clinical Pathology published by Wiley Periodicals LLC on behalf of American Society for Veterinary Clinical Pathology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Chemistry Harr, Kendal E. Gordon, Sonya G. Baumwart, Ryan D. Feldgreber, Ross Spiro, Matthew R. Analytical validation of a novel point‐of‐care immunoassay for canine N‐terminal pro‐brain natriuretic peptide analysis |
title | Analytical validation of a novel point‐of‐care immunoassay for canine N‐terminal pro‐brain natriuretic peptide analysis |
title_full | Analytical validation of a novel point‐of‐care immunoassay for canine N‐terminal pro‐brain natriuretic peptide analysis |
title_fullStr | Analytical validation of a novel point‐of‐care immunoassay for canine N‐terminal pro‐brain natriuretic peptide analysis |
title_full_unstemmed | Analytical validation of a novel point‐of‐care immunoassay for canine N‐terminal pro‐brain natriuretic peptide analysis |
title_short | Analytical validation of a novel point‐of‐care immunoassay for canine N‐terminal pro‐brain natriuretic peptide analysis |
title_sort | analytical validation of a novel point‐of‐care immunoassay for canine n‐terminal pro‐brain natriuretic peptide analysis |
topic | Clinical Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544283/ https://www.ncbi.nlm.nih.gov/pubmed/35312100 http://dx.doi.org/10.1111/vcp.13101 |
work_keys_str_mv | AT harrkendale analyticalvalidationofanovelpointofcareimmunoassayforcaninenterminalprobrainnatriureticpeptideanalysis AT gordonsonyag analyticalvalidationofanovelpointofcareimmunoassayforcaninenterminalprobrainnatriureticpeptideanalysis AT baumwartryand analyticalvalidationofanovelpointofcareimmunoassayforcaninenterminalprobrainnatriureticpeptideanalysis AT feldgreberross analyticalvalidationofanovelpointofcareimmunoassayforcaninenterminalprobrainnatriureticpeptideanalysis AT spiromatthewr analyticalvalidationofanovelpointofcareimmunoassayforcaninenterminalprobrainnatriureticpeptideanalysis |